358 related articles for article (PubMed ID: 25354725)
21. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.
Visser J; van Baarle D; Hoogeboom BN; Reesink N; Klip H; Schuuring E; Nijhuis E; Pawlita M; Bungener L; de Vries-Idema J; Nijman H; Miedema F; Daemen T; van der Zee A
Int J Cancer; 2006 May; 118(10):2529-37. PubMed ID: 16353143
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.
Trimble CL; Peng S; Kos F; Gravitt P; Viscidi R; Sugar E; Pardoll D; Wu TC
Clin Cancer Res; 2009 Jan; 15(1):361-7. PubMed ID: 19118066
[TBL] [Abstract][Full Text] [Related]
24. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670
[TBL] [Abstract][Full Text] [Related]
25. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.
Harper DM; Nieminen P; Donders G; Einstein MH; Garcia F; Huh WK; Stoler MH; Glavini K; Attley G; Limacher JM; Bastien B; Calleja E
Gynecol Oncol; 2019 Jun; 153(3):521-529. PubMed ID: 30955915
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in human papillomavirus vaccines.
Mahdavi A; Monk BJ
Curr Oncol Rep; 2006 Nov; 8(6):465-72. PubMed ID: 17091565
[TBL] [Abstract][Full Text] [Related]
29. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
30. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
31. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic HPV DNA vaccines.
Lin K; Roosinovich E; Ma B; Hung CF; Wu TC
Immunol Res; 2010 Jul; 47(1-3):86-112. PubMed ID: 20066511
[TBL] [Abstract][Full Text] [Related]
33. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
[TBL] [Abstract][Full Text] [Related]
35. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.
Van Doorslaer K; Reimers LL; Studentsov YY; Einstein MH; Burk RD
Gynecol Oncol; 2010 Feb; 116(2):208-12. PubMed ID: 19555999
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
Cornelison TL
Curr Opin Oncol; 2000 Sep; 12(5):466-73. PubMed ID: 10975555
[TBL] [Abstract][Full Text] [Related]
37. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
[TBL] [Abstract][Full Text] [Related]
38. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.
Jemon K; Young V; Wilson M; McKee S; Ward V; Baird M; Young S; Hibma M
PLoS One; 2013; 8(6):e66866. PubMed ID: 23799135
[TBL] [Abstract][Full Text] [Related]
39. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
[TBL] [Abstract][Full Text] [Related]
40. Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus.
Melief CJ
Cancer J; 2011; 17(5):300-1. PubMed ID: 21952279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
